Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

This study is testing a combination of two drugs — axatilimab (an immune-targeting drug) and olaparib (a PARP inhibitor that blocks DNA repair in cancer cells) — in people with advanced breast cancer that is HER2-negative and has a BRCA1, BRCA2, or PALB2 gene mutation. **You may be eligible if...** - You have metastatic or inoperable HER2-negative breast cancer (including HER2-low) - You have a confirmed BRCA1, BRCA2, or PALB2 gene mutation - Your hormone receptor-positive cancer has stopped responding to hormonal treatments - You have adequate organ function **You may NOT be eligible if...** - You have previously been treated with a PARP inhibitor (like olaparib or niraparib) - You have active brain metastases requiring treatment - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.